发明名称 |
STABILIZED ULTRA-RAPID-ACTING INSULIN FORMULATIONS |
摘要 |
Compositions and methods for enhancing the stability of rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“EDTA”), a dissolution/stabilization agent such as citric acid, a magnesium salt, a zinc compound and, optionally, additional excipients. New presentations include rapid acting concentrated insulin formulations and a way to enhance the absorption of commercially available rapid acting analog formulations while maintaining insulin stability. |
申请公布号 |
US2015273022(A1) |
申请公布日期 |
2015.10.01 |
申请号 |
US201514618619 |
申请日期 |
2015.02.10 |
申请人 |
Biodel Inc. |
发明人 |
Wilson Bryan R.;Ravula Pragati;Li Ming;Pohl Roderike;Hauser Robert |
分类号 |
A61K38/28;A61K47/18;A61K33/06;A61K47/02;A61K47/22;A61K9/00;A61K47/12 |
主分类号 |
A61K38/28 |
代理机构 |
|
代理人 |
|
主权项 |
1. An injectable insulin formulation comprising an effective amount of a dissolution/stabilizing agent and an effective amount of a chelator to enhance the stability of the insulin as measured by loss of insulin potency of less than 5 IU at 7 days at 37° C. |
地址 |
Danbury CT US |